A detailed history of Reynders Mc Veigh Capital Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Reynders Mc Veigh Capital Management, LLC holds 96,979 shares of CRSP stock, worth $5.15 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares
96,979
Previous 92,048 5.36%
Holding current value
$5.15 Million
Previous $5.76 Million 14.73%
% of portfolio
0.38%
Previous 0.36%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$60.67 - $89.12 $5.88 Million - $8.64 Million
96,979 New
96,979 $6.61 Million
Q4 2023

Feb 07, 2024

BUY
$38.62 - $72.18 $612,899 - $1.15 Million
15,870 Added 20.83%
92,048 $5.76 Million
Q3 2023

Nov 09, 2023

BUY
$45.39 - $59.0 $1.19 Million - $1.54 Million
26,180 Added 52.36%
76,178 $3.46 Million
Q2 2023

Aug 09, 2023

BUY
$43.47 - $67.77 $1.35 Million - $2.11 Million
31,094 Added 164.48%
49,998 $2.81 Million
Q1 2023

May 03, 2023

BUY
$41.0 - $56.12 $775,064 - $1.06 Million
18,904 New
18,904 $855,000
Q3 2022

Nov 08, 2022

BUY
$61.1 - $83.78 $188,493 - $258,461
3,085 New
3,085 $202,000
Q2 2022

Aug 05, 2022

SELL
$43.23 - $73.83 $202,316 - $345,524
-4,680 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$53.19 - $79.24 $96,539 - $143,820
1,815 Added 63.35%
4,680 $294,000
Q4 2021

Feb 11, 2022

BUY
$70.09 - $111.29 $11,564 - $18,362
165 Added 6.11%
2,865 $217,000
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $10,469 - $14,880
95 Added 3.65%
2,700 $302,000
Q2 2021

Aug 12, 2021

BUY
$100.84 - $161.89 $14,621 - $23,474
145 Added 5.89%
2,605 $422,000
Q1 2021

May 07, 2021

BUY
$110.72 - $210.04 $2,214 - $4,200
20 Added 0.82%
2,460 $300,000
Q4 2020

Feb 10, 2021

SELL
$79.67 - $173.23 $3,983 - $8,661
-50 Reduced 2.01%
2,440 $374,000
Q3 2020

Oct 28, 2020

BUY
$78.5 - $100.64 $195,465 - $250,593
2,490 New
2,490 $208,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.14B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Reynders Mc Veigh Capital Management, LLC Portfolio

Follow Reynders Mc Veigh Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.